
Opinion|Videos|August 6, 2026
CNS Disease
Author(s)Sandip Patel, MD, Chul Kim, MD
This segment covers central nervous system (CNS) involvement in EGFR-mutated NSCLC.
Advertisement
Episodes in this series
This segment covers central nervous system (CNS) involvement in EGFR-mutated NSCLC. The panelists discuss how large, symptomatic brain involvement warrants consult of radiation and neurosurgery colleagues, while small, asymptomatic brain metastases may reasonably be treated with systemic therapy. CNS disease is a high-risk feature favoring combination therapy, and the importance of obtaining MRI of the brain is emphasized given the risk of missing occult brain metastasis.
Advertisement
Related to this article

Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5


